Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 665

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 665
---
 Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance
Committee and as a member of the audit committee. Dr. Lewis-Hall served as a member of the board of directors for Exact Sciences Corporation
(Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline
Committees; a member of 1LifeHealthCare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating
and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC)
from 2014 to 2017.

Dr.
Lewis-Hall holds an M.D. from Howard University College of Medicine and a B.A. in natural sciences from the Johns Hopkins University.
The Company believes Dr. Lewis-Hall is qualified to serve on the Board based on her expertise and experience in the biopharmaceutical
industry and her leadership experience as a senior executive at various biopharmaceutical companies.

73

Faith
L. Charles. Ms. Charles has served as a member of our board of directors since September 2023. She has been a corporate
transactions and securities partner at the law firm of Thompson Hine LLP since 2010. She leads Thompson Hine’s Life Sciences practice
and co-heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally.
Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic
collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the industry as an astute business
advisor, providing valuable insights into capital markets, corporate governance and strategic development. Ms. Charles has been a member
of the board of directors of: CNS Pharmaceuticals, Inc. (Nasdaq: CNSP), a biotechnology company developing novel treatments for cancers
of the brain and central nervous system, since December 2022; Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company
specializing in developing and commercializing therapies for the treatment of the central nervous system, since May 2022; and Abeona
Therapeutics, Inc. (Nasdaq: ABEO), a